Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | KDR C482R |
| Therapy | Crizotinib + Pazopanib |
| Indication/Tumor Type | clear cell renal cell carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| KDR C482R | clear cell renal cell carcinoma | predicted - sensitive | Crizotinib + Pazopanib | Case Reports/Case Series | Actionable | In a Phase I trial, Xalkori (crizotinib) and Votrient (pazopanib) combination treatment resulted in a partial response lasting 36 weeks in a patient with clear cell renal cancer harboring KDR (VEGFR2) C482R, KIT M541L, and VHL D121Y, who achieved stable disease for 1 year on Votrient (pazopanib) monotherapy previously (PMID: 33994796; NCT01548144). | 33994796 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (33994796) | A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies. | Full reference... |